(Total Views: 105)
Posted On: 11/12/2021 8:30:48 AM
Post# of 89382

$CGEN News Article - Compugen Presents Preliminary Results from Phase 1 Dose Escalation Monotherapy Study of COM902 a High Affinity Anti-TIGIT Antibody at SITC 2021 https://marketwirenews.com/news-releases/comp...98565.html


My Twitter: WhyteStocks